title: Non FcR-binding murine antihuman CD3 monoclonal antibody is capable of productive TCR signalling and induces proliferation in the presence of costimulation.
abstract: CLB T3/4.A is a non FcR-binding CD3 mAb of the murine IgA isotype, which may be used as an alternative for the mitogenic OKT3 mAb in the treatment of acute cellular rejection after organ transplantation. We studied TCR signalling and T cell activation in response to T3/4.A in normal human PBMC in vitro. T3/4.A induced a rapid rise in free cytoplasmic Ca(2+), not different from the response to mitogenic CD3 mAb. However, protein tyrosine phosphorylation and, particularly, MAPK activation, were reduced as compared to mitogenic CD3 mAb. T3/4.A enhanced expression of both CD69 and CD25, but proliferation and detectable cytokine production did not occur. Addition of either CD28 mAb or IL-2 induced a strong proliferative response, which was accompanied by cytokine production. At higher mAb concentrations, T cell activation decreased, which correlated with TCR downmodulation. To exclude the possibility that activation by T3/4.A depends on interaction of murine IgA Fc with as yet unknown FcR, we showed that also with CD3 mAb F(ab')2 fragments upregulation of activation molecules occurred, as well as proliferation in the presence of costimulation. We conclude that the non FcR-binding murine IgA mAb T3/4.A acts as a partial agonist and leads to proliferation and cytokine production only in the presence of appropriate costimuli. These findings may explain the mitigated cytokine release syndrome observed in vivo with some nonmitogenic CD3 mAbs.
authors: Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands.
authors: R T
authors: RT
authors: Meijer
authors: S L
authors: SL
authors: Yong
authors: I J
authors: IJ
authors: ten Berge
authors: R A
authors: RA
authors: van Lier
authors: P T
authors: PT
authors: Schellekens
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D018106:CD28 Antigens / Q000378:metabolism; D017252:CD3 Complex / Q000276:immunology*; D006084:Graft Rejection / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007167:Immunotherapy / Q000379:methods; D008213:Lymphocyte Activation / Q000276:immunology*; D051379:Mice; D016853:Muromonab-CD3 / Q000276:immunology / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell / Q000378:metabolism*; D011961:Receptors, Fc / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D000911:Antibodies, Monoclonal; D018106:CD28 Antigens; D017252:CD3 Complex; D007070:Immunoglobulin A; D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell; D011961:Receptors, Fc